Harold J. Burstein, Breast Cancer Specialist and Professor at Dana-Farber Cancer Institute and Harvard Medical School, shared Matthew Herper’s, Senior Writer at STAT, post on X:
“The issues here are more market than medical. To date, the test does not work to facilitate early detection of cancer. The study did not meet its primary endpoint. The biggest signal was in colorectal cancer but the UK (where study was done) does not have widespread screening colonoscopy, as does US, so meaning unclear for American health.
See American Society of Clinical Oncology (ASCO) data slides for Galleri study.
See Lancet editorial.”
Quoting Matthew Herper:
“Grail, Inc. shares are surging today ahead of a key FDA meeting on the company’s blood test to detect multiple forms of cancer.
Based on the FDA briefing documents posted today, that’s understandable – they are more friendly to Grail and its test, Galleri, than many might have expected.”
Read more articles featuring Harold J. Burstein on OncoDaily.